This clinical trial is focused on studying a condition known as esophageal atresia, which is a birth defect where a baby is born with an incomplete esophagus. After surgical repair, some children may develop a problem called strictures, which are narrowings in the esophagus that can make swallowing difficult. The study aims to find out if using a treatment called intralesional steroid injections can help prevent these strictures from becoming difficult to treat, known as refractory strictures. The medication used in this study is called triamcinolone acetonide, which is given as an injection directly into the affected area.

The purpose of the study is to see if these injections can reduce the number of procedures needed to widen the esophagus, called dilatations, over a period of 28 days. Children who have undergone surgery for esophageal atresia and are experiencing strictures may receive either the steroid injection or a placebo. The study will monitor the number of dilatations each child needs during the study period, which lasts for six months after the initial treatment.

Participants in the study will receive the treatment through a local injection, which means the medication is delivered directly to the site where it is needed. The study will help determine if this approach can effectively reduce the need for repeated procedures and improve the quality of life for children with esophageal atresia. The trial is known as the STEPS-EA trial and is being conducted to gather important information that could benefit future patients with this condition.